Media stories about Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG) have trended positive on Saturday, Accern Sentiment reports. The research firm identifies positive and negative press coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Tetralogic Pharmaceuticals Corp earned a news impact score of 0.35 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 46.0176802999127 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Tetralogic Pharmaceuticals Corp (NASDAQ TLOG) traded up 21.21% on Friday, hitting $0.02. 958,083 shares of the company traded hands. The stock’s 50-day moving average is $0.02 and its 200 day moving average is $0.03. The stock’s market cap is $495380.00. Tetralogic Pharmaceuticals Corp has a 12 month low of $0.01 and a 12 month high of $0.20.

TRADEMARK VIOLATION NOTICE: “Tetralogic Pharmaceuticals Corp (TLOG) Earns Daily Media Sentiment Score of 0.35” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark laws. The original version of this news story can be accessed at

Tetralogic Pharmaceuticals Corp Company Profile

TetraLogic Pharmaceuticals Corporation is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics in oncology, infectious diseases and autoimmune diseases. The Company’s segment is the identification and development of novel small molecule therapies in oncology and infectious diseases.

Insider Buying and Selling by Quarter for Tetralogic Pharmaceuticals Corp (NASDAQ:TLOG)

Receive News & Stock Ratings for Tetralogic Pharmaceuticals Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetralogic Pharmaceuticals Corp and related stocks with our FREE daily email newsletter.